EAT is up +49.38%% since April’24 pick View All Top Buy Picks
Currently predicting for Thu, 27 Jun 2024

Trading levels for HNR1.F

Fibonacci Support & Resistance Levels

Level Price
R3 240.43 1.58%
R2 239.10 1.01%
R1 238.27 0.663%
Price 236.70
S1 235.60 -0.466%
S2 234.77 -0.82%
S3 233.43 -1.38%

Accumulated Volume Support & Resistance Levels

Level Price
R3 253.70 7.18%
R2 239.70 1.27%
R1 237.30 0.253%
Price 236.70
S1 235.80 -0.380%
S2 228.20 -3.59%
S3 227.00 -4.10%

HNR1.F Predictions History

StockInvest.us BE THE FIRST TO PREDICT

The excellent way of becoming a better trader


  • Easy to use
  • Enhance your skills
  • Predict as many as you like
  • Request predictions
  • Gather points
  • Learn to time your buy and sells

I wonder how good you are and if you can beat me?

Now it is your turn to become professional by doing what professionals do - Exercise

Best regards,

Jim - Co-founder of StockInvest.us [ See tutorial video ]

Click to get the best stock tips daily for free!

About Hannover Rück SE

Hannover Rück SE Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine,... HNR1.F Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT